Publications

Publication list

Sort by: Date | Author | Title

Hnisz D, Weintraub AS, Day DS, Valton AL, Bak RO, Li CH et al. Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science. 2016 Mar 25;351(6280):1454-1458. doi: 10.1126/science.aad9024
Hinke DM, Dorset SR, Bratland E, Wolff JH, Olsnes AM, Mikkelsen JG et al. CXCR2 deficiency with myelokathexis caused by a novel variant: correction via CRISPR/Cas9. Haematologica. 2025 Aug 28;111(2):738-744. Epub 2025 Aug 28. doi: 10.3324/haematol.2025.288111
Hernández SS, Jakobsen MR, Bak RO. Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy. International Journal of Molecular Sciences . 2022 Sept;23(19):11397. doi: 10.3390/ijms231911397
Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nature Biotechnology. 2015 Jun 29. doi: 10.1038/nbt.3290
Hendel A, Bak RO. Editorial: CRISPR and beyond: Cutting-edge technologies for gene correction in therapeutic applications. Frontiers in Genome Editing. 2023;5:1203864. doi: 10.3389/fgeed.2023.1203864
He M, Roussak K, Ma F, Borcherding N, Garin V, White M et al. CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses. Science. 2023 Feb 17;379(6633):eabg2752. doi: 10.1126/science.abg2752
Gomez-Ospina N, Scharenberg SG, Mostrel N, Bak RO, Mantri S, Quadros RM et al. Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I. Nature Communications. 2019 Dec 1;10(1):4045. 4045. doi: 10.1038/s41467-019-11962-8
Gao Z, Bak RO. Integration of large genetic payloads using prime editing and site-specific integrases. Nature Protocols. 2025 Jun;20(6):1391-1392. Epub 2024 Dec 15. doi: 10.1038/s41596-024-01094-9
Galdos FX, Lee C, Lee S, Paige S, Goodyer W, Xu S et al. Combined lineage tracing and scRNA-seq reveals unexpected first heart field predominance of human iPSC differentiation. eLife. 2023 Jun 7;12:e80075. doi: 10.7554/eLife.80075
Dudek AM, Feist WN, Sasu EJ, Luna SE, Ben-Efraim K, Bak RO et al. A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection. Cell Stem Cell. 2024 Apr;31(4):499-518.e6. doi: 10.1016/j.stem.2024.03.002
Dorset SR, Bak RO. The p53 challenge of hematopoietic stem cell gene editing. Molecular Therapy Methods and Clinical Development. 2023 Sept;30:83-89. doi: 10.1016/j.omtm.2023.06.003
Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. 2016 Nov 17;539(7629):384-389. doi: 10.1038/nature20134
Dever DP, Scharenberg SG, Camarena J, Kildebeck EJ, Clark JT, Martin RM et al. CRISPR/Cas9 Genome Engineering in Engraftable Human Brain-Derived Neural Stem Cells. iScience. 2019 May 31;15:524-535. doi: 10.1016/j.isci.2019.04.036
Dalsgaard T, Kaadt CRC, Askou AL, Bak RO, Andersen PO, Hougaard D et al. Improved Lentiviral Gene Delivery to Mouse Liver by Hydrodynamic Vector Injection through Tail Vein. Molecular Therapy - Nucleic Acids. 2018 Sept 7;12:672-683. Epub 2018 Aug 6. doi: 10.1016/j.omtn.2018.07.005
Cromer MK, Vaidyanathan S, Ryan DE, Curry B, Lucas AB, Camarena J et al. Global Transcriptional Response to CRISPR/Cas9-AAV6-Based Genome Editing in CD34 Hematopoietic Stem and Progenitor Cells. Molecular Therapy. 2018;26(10):2431-2442. doi: 10.1016/j.ymthe.2018.06.002
Cromer MK, Camarena J, Martin RM, Lesch BJ, Vakulskas CA, Bode NM et al. Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells. Nature Medicine. 2021 Apr;27(4):677-687. Epub 2021 Mar 18. doi: 10.1038/s41591-021-01284-y
Charlesworth CT, Camarena J, Cromer MK, Vaidyanathan S, Bak RO, Carte JM et al. Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting. Molecular Therapy - Nucleic Acids. 2018 Sept 7;12:89-104. doi: 10.1016/j.omtn.2018.04.017
Chai C, Liang L, Mikkelsen NS, Wang W, Zhao W, Sun C et al. Single-cell transcriptome analysis of epithelial, immune, and stromal signatures and interactions in human ovarian cancer. Communications Biology. 2024 Jan 26;7(1):131. 131. doi: 10.1038/s42003-024-05826-1
Cavazza A, Hendel A, Bak RO, Rio P, Güell M, Lainšček D et al. Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi. Molecular Therapy Nucleic Acids. 2023 Dec 12;34:102066. 102066. doi: 10.1016/j.omtn.2023.102066, 10.1016/j.omtn.2023.102066
Cai H, Zhang B, Ahrenfeldt J, Joseph JV, Riedel M, Gao Z et al. CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression. Nature Communications. 2024 Dec;15(1):2088. doi: 10.1038/s41467-024-46370-0, 10.1038/s41467-024-46370-0
Bendixen L, Jensen TI, Bak RO. CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi. Molecular Therapy. 2023 Jul;31(7):1920-1937. Epub 2023 Mar 23. doi: 10.1016/j.ymthe.2023.03.024
Bak RO, Hollensen AK, Mikkelsen JG. Managing MicroRNAs with Vector-Encoded Decoy-Type Inhibitors. Molecular Therapy. 2013 Aug;21(8):1478-85. doi: 10.1038/mt.2013.113
Bak R, Mikkelsen JG. miRNA sponges: soaking up miRNAs for regulation of gene expression. Wiley Interdisciplinary Reviews: RNA. 2013 Dec 23. doi: 10.1002/wrna.1213
Bak RO, Porteus MH. CRISPR-Mediated Integration of Large Gene Cassettes Using AAV Donor Vectors. Cell Reports. 2017 Jul 18;20(3):750-756. doi: 10.1016/j.celrep.2017.06.064
Bak RO, Dever DP, Reinisch A, Cruz Hernandez D, Majeti R, Porteus MH. Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6. eLife. 2017 Sept 28;6:e27873. doi: 10.7554/eLife.27873
Bak R, Dever DP, Porteus MH. CRISPR/Cas9 genome editing in human hematopoietic stem cells. Nature Protocols (Print). 2018;13(2):358-376. doi: 10.1038/nprot.2017.143
Bak RO, Gomez-Ospina N, Porteus MH. Gene Editing on Center Stage. Trends in Genetics. 2018;34(8):600-611. doi: 10.1016/j.tig.2018.05.004
Bak RO. The Potential of CRISPR/Cas9 in Hematotherapy. Stem Cells and Development. 2019;28(11):710-711. Epub 2019 May 15. doi: 10.1089/scd.2019.0079
Bak RO, Dever DP, Porteus MH. Therapeutic Genome Editing in Human Hematopoietic Stem and Progenitor Cells. In Genome Editing and Engineering: From TALENs, ZFNs and CRISPRs to Molecular Surgery. Cambridge University Press. 2018. p. 301-312 doi: 10.1017/9781316756300.022
Axelgaard E, Jensen TI, Bak RO. Therapeutic gene editing in haematological disorders with CRISPR/Cas9. British Journal of Haematology. 2019;185(5):821-835. Epub 2019 Mar 13. doi: 10.1111/bjh.15851